111 completed. 111 Phase 3, 28 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 111 | Completed 111 |
| Phase 2 | 28 | Completed 28 |
Follow Covid19: new trials by email Literature Review of Covid19 trials Research Report on Covid19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Placebo, Metformin - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 3214 | 2023-09-05 | 2025-11-18 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) Placebo, Montelukast - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1453 | 2023-01-27 | 2025-01-17 |
| SARS-CoV-2 and Acetylsalicylic Acid (SARA) Low-dose acetylsalicylic acid, Placebo - SARS-CoV2 Infection, Covid19 | Phase 3 | Completed | Barcelona Institute for Global Health | 38 | 2022-09-14 | 2024-08-15 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100) Fluvoxamine, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1208 | 2022-08-25 | 2024-11-15 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) Ivermectin, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1459 | 2022-02-16 | 2023-11-03 |
| the Safety and Efficacy of Meplazumab in Patients With COVID-19 Meplazumab for Injection, Sterile normal saline (0.9%) - Covid19 | Phase 2 / Phase 3 | Completed | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | 150 | 2022-01-21 | 2023-09-15 |
| A Phase III Confirmatory Study of K-237 K-237 0.3-0.4mg/kg (once daily), Placebo 0.3-0.4mg/kg (once daily) - Covid19 | Phase 3 | Completed | Kowa Company, Ltd. | 1030 | 2021-10-22 | 2024-05-20 |
| Combined Antihistaminics Therapy in COVID 19 Patients Loratadine, Famotidine - Covid19 | Phase 2 / Phase 3 | Completed | Ain Shams University | 214 | 2021-09-13 | 2023-08-25 |
| Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose), ChAdOx1-S not less than 2.5 × 10^8 infectious units - Covid19 | Phase 3 | Completed | SK Bioscience Co., Ltd. | 4036 | 2021-08-30 | 2024-04-08 |
| Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, Saline placebo - Covid19 | Phase 3 | Completed | Cinnagen | 16876 | 2021-08-07 | 2022-10-13 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone) Fluticasone, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1407 | 2021-08-06 | 2023-06-18 |
| Lipid Emulsion Infusion and COVID-19 Patients SMOFlipid, 0.9% saline - Covid19 | Phase 3 | Completed | Assiut University | 74 | 2021-07-05 | 2021-09-28 |
| Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine TURCOVAC, CoronaVac - Covid19 | Phase 3 | Completed | Health Institutes of Turkey | 1290 | 2021-06-21 | 2024-02-29 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine) Fluvoxamine, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1331 | 2021-06-08 | 2023-09-26 |
| ACTIV-6: COVID-19 Study of Repurposed Medications Ivermectin, Fluvoxamine, Fluticasone - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 10956 | 2021-06-08 | 2025-11-17 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) Ivermectin, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1800 | 2021-06-08 | 2023-06-13 |
| Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC) Ivermectin, Placebo - Covid19 | Phase 2 / Phase 3 | Completed | Ministry of Public Health, Argentina | 172 | 2021-06-01 | 2021-12-07 |
| Glutamine Supplementation and Short-term Mortality in Covid-19 Standard enteral nutrition, Glutamine - Covid19 | Phase 3 | Completed | Assiut University | 60 | 2021-05-30 | 2021-11-05 |
| Impact of Steroids on Inflammatory Response in Covid-19 Dexamethasone, Methylprednisolone - Covid19 | Phase 3 | Completed | Assiut University | 60 | 2021-05-28 | 2021-09-08 |
| Xylocaine to Freeze During Unpleasant Nasopharyngeal Swabs Xylocaine, Placebo - Covid19 | Phase 2 / Phase 3 | Completed | Evelyne D.Trottier | 88 | 2021-05-11 | 2021-09-27 |
Showing 20 of 111. Sign in to see all of them.
COVID-19 (111) · Severe Acute Respiratory Syndrome (15) · Coronavirus Infections (13) · Virus Diseases (8) · RNA Virus Infections (6) · Coronaviridae Infections (5) · Nidovirales Infections (5) · Pneumonia (4) · Respiratory Insufficiency (3) · Communicable Diseases (2) · Cytokine Release Syndrome (2) · Inflammation (2) · Neoplasms (2) · Thrombosis (2) · Anosmia (1)
Infections (111) · Lung Diseases (111) · Respiratory Tract Diseases (111) · Respiratory Tract Infections (111) · Pneumonia, Viral (110) · Pneumonia (107) · Coronaviridae Infections (106) · Nidovirales Infections (106) · RNA Virus Infections (105) · Virus Diseases (103) · Coronavirus Infections (98) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (9) · Cardiovascular Diseases (5) · Vascular Diseases (5)
Ivermectin (9) · Standard of Care (9) · remdesivir (6) · Fluvoxamine (5) · Azithromycin (4) · Hydroxychloroquine (4) · favipiravir (4) · Adrenal Cortex Hormones (3) · Dexamethasone (3) · Heparin (3) · Metformin (3) · Methylprednisolone (3) · Sodium Chloride (3) · Vitamin D (3) · sotrovimab (3)
Susanna Naggie, MD (8) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Assiut University (3) · University of Sao Paulo (3) · Ain Shams University (2) · Australian National University (2) · Coordinación de Investigación en Salud, Mexico (2) · CureVac (2) · D'Or Institute for Research and Education (2) · Health Institutes of Turkey (2) · Pontificia Universidad Catolica de Chile (2) · ARCA Biopharma, Inc. (1) · ASST Fatebenefratelli Sacco (1) · Almaza Military Fever Hospital (1) · Appili Therapeutics Inc. (1)
United States (29) · Brazil (16) · Mexico (11) · Egypt (10) · Argentina (9) · Italy (8) · Spain (6) · Canada (5) · United Kingdom (5) · Bangladesh (3) · Denmark (3) · Germany (3) · Greece (3) · Indonesia (3) · Peru (3)
Adrian Hernandez, MD (8) · Susanna Naggie, MD (8) · Prof. James Neaton (4) · Samuel Brown, MD (3) · Andy Goren, MD (2) · Frank MP van Haren, MD, PhD (2) · Marcelo Silveira, MD, PhD (2) · Omar Soliman, MD (2) · Abdelhakim F Ghallab, MD (1) · Abdelrahman A Abdelalim, MD (1) · Akter Kamal, MD, PhD (1) · Alberto M Borobia, MD, PhD (1)
PMID 34473343, PMID 35244208, PMID 35713300, PMID 37591523, PMID 35180412, PMID 12480795, PMID 1593279, PMID 15992957, PMID 16103157, PMID 16103202, PMID 18446504, PMID 22417684, PMID 23320022, PMID 23769930, PMID 24161512, PMID 25645191, PMID 26491864, PMID 26988202, PMID 28934952, PMID 31023272, PMID 31282542, PMID 31442620, PMID 32142651, PMID 32187464, PMID 32251768, PMID 32282022, PMID 32293834, PMID 32313880, PMID 32360300, PMID 32407672, PMID 32992075, PMID 33234158, PMID 33356051, PMID 33377218, PMID 33390932, PMID 33429174, PMID 33502773, PMID 33583027, PMID 33734299, PMID 33983065, PMID 34133856, PMID 34215210, PMID 34222849, PMID 34387679, PMID 34388972, PMID 34407339, PMID 34480880, PMID 34539185, PMID 34658014, PMID 34659237
U24TR001608 (8), 1OT2HL156812-01 (1)